Citadel Advisors LLC boosted its holdings in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 61.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 147,047 shares of the biotechnology company’s stock after acquiring an additional 55,783 shares during the quarter. Citadel Advisors LLC owned approximately 0.42% of Five Prime Therapeutics worth $2,325,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of FPRX. Rockefeller Capital Management L.P. acquired a new position in Five Prime Therapeutics during the first quarter valued at approximately $111,000. Quantbot Technologies LP grew its holdings in Five Prime Therapeutics by 361.5% during the first quarter. Quantbot Technologies LP now owns 7,347 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 5,755 shares during the last quarter. Mackay Shields LLC acquired a new position in Five Prime Therapeutics during the first quarter valued at approximately $317,000. Fox Run Management L.L.C. acquired a new position in Five Prime Therapeutics during the second quarter valued at approximately $379,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Five Prime Therapeutics by 17.8% during the first quarter. The Manufacturers Life Insurance Company now owns 25,032 shares of the biotechnology company’s stock valued at $430,000 after purchasing an additional 3,782 shares during the last quarter. 86.31% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have commented on the company. BidaskClub upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, June 27th. Wedbush assumed coverage on Five Prime Therapeutics in a report on Thursday, May 17th. They set a “neutral” rating and a $17.00 price target on the stock. Zacks Investment Research downgraded Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 17th. JPMorgan Chase & Co. assumed coverage on Five Prime Therapeutics in a report on Friday, June 15th. They set a “neutral” rating and a $19.00 price target on the stock. Finally, Raymond James assumed coverage on Five Prime Therapeutics in a report on Thursday, June 28th. They set a “market perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $34.50.
Shares of Five Prime Therapeutics stock opened at $13.10 on Friday. The firm has a market capitalization of $504.16 million, a PE ratio of -2.51 and a beta of 3.24. Five Prime Therapeutics Inc has a 1 year low of $12.66 and a 1 year high of $48.87.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.30. The business had revenue of $7.58 million for the quarter, compared to the consensus estimate of $5.87 million. Five Prime Therapeutics had a negative net margin of 206.02% and a negative return on equity of 40.61%. research analysts expect that Five Prime Therapeutics Inc will post -4.02 EPS for the current year.
Five Prime Therapeutics Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
Further Reading: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.